Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

References

• FerlayJShinHRBrayFFormanDMathersCParkinDM2008GLOBOCAN v20, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 [homepage on the Internet]Lyon, FranceInternational Agency for Research on Cancer2010 Available from: http://globocan.iarc.frAccessed April 22, 2013.
   Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• NaumannRWColemanRLManagement strategies for recurrent platinum-resistant ovarian cancerDrugs201171111397141221812505
   PubMed Web of Science ®Google Scholar
• McGuireWPRowinskyEKRosensheinNBTaxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasmsAnn Int Med198911142732792569287
   PubMed Web of Science ®Google Scholar
• ThigpenJTBlessingJABallHHummelSJBarrettRJPhase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group studyJ Clin Oncol1994129174817537916038
   PubMed Web of Science ®Google Scholar
• RowinskyEKDonehowerRCPaclitaxel (taxol)N Engl J Med199533215100410147885406
   PubMed Web of Science ®Google Scholar
• Gynecologic Oncology GroupMarkmanMBlessingJPhase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group studyGynecol Oncol2006101343644016325893
   PubMed Web of Science ®Google Scholar
• BairdRDTanDSKayeSBWeekly paclitaxel in the treatment of recurrent ovarian cancerNat Rev Clin Oncol201071057558220683437
   PubMed Web of Science ®Google Scholar
• RosenbergPAnderssonHBomanKRandomized trial of single-agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinumActa Oncol200241541842412442916
   PubMed Web of Science ®Google Scholar
• EisenhauerEAten Bokkel HuininkWWEuropean-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionJ Clin Oncol19941212265426667989941
   PubMed Web of Science ®Google Scholar
• LortholaryALargillierRWeberBGINECO group FranceWeekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)Ann Oncol201223234635221562072
   PubMed Web of Science ®Google Scholar
• ten Bokkel HuininkWGoreMCarmichaelJTopotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancerJ Clin Oncol1997156218321939196130
   PubMed Web of Science ®Google Scholar
• ArmstrongDKTopotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicityOncologist200491334214755013
   PubMed Web of Science ®Google Scholar
• HoskinsPEisenhauerEBeareSRandomized phase ll study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group studyJ Clin Oncol1998166223322379626225
   PubMed Web of Science ®Google Scholar
• MarkmanMKennedyAWebsterKKulpBPetersonGBelinsonJPhase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancerGynecol Oncol200079111611911006042
   PubMed Web of Science ®Google Scholar
• MuggiaFMHainsworthJDJeffersSPhase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulationJ Clin Oncol19971539879939060537
   PubMed Web of Science ®Google Scholar
• GordonANGranaiCORosePGPhase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancerJ Clin Oncol200018173093310010963637
   PubMed Web of Science ®Google Scholar
• GordonANTondaMSunSRackoffWDoxil Study 30–49 InvestigatorsLong-term survival advantage for woman treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol20049511815385103
   PubMed Web of Science ®Google Scholar
• GordonANFleagleJTGuthrieDParkinDEGoreMELacaveAJRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol200119143312332211454878
   PubMed Web of Science ®Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol200725192811281817602086
   PubMed Web of Science ®Google Scholar
• FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol200826689089618281662
   PubMed Web of Science ®Google Scholar
• SatyamAHockerMDKane-MaguireKAMorganASVillarHOLyttleMHDesign, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferaseJ Med Chem1996398173617478648613
   PubMed Web of Science ®Google Scholar
• LyttleMHSatyamAHockerMDGlutathione-S-transferase activates novel alkylating agentsJ Med Chem19943710150115078182709
   PubMed Web of Science ®Google Scholar
• LabordeEGlutathione transferases as mediators of signaling pathways involved in cell proliferation and cell deathCell Death Differ20101791373138020596078
   PubMed Web of Science ®Google Scholar
• VergoteIFinklerNdel CampoJASSIST-1 Study GroupPhase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerEur J Cancer2009452324233219515553
   PubMed Web of Science ®Google Scholar
• VergoteIFinklerNJHallJBRandomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancerInt J Gynecol Cancer201020577278020973267
   PubMed Web of Science ®Google Scholar
• De GeestKBlessingJAMorrisRTPhase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group studyJ Clin Oncol201028114915319917861
   PubMed Web of Science ®Google Scholar
• ColomboNKutarskaEDimopoulosMRandomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerJ Clin Oncol201230313841384722987083
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBAURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)J Clin Oncol201230Suppl 15 abstract LBA5002
   Google Scholar
• ColemanRLDuskaLRRamirezPTPhase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancerJ Clin Oncol201129Suppl 15 Abstract 5017
   Web of Science ®Google Scholar
• FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• BirrerMJKonstantinopoulosPPensonRTA phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancerJ Clin Oncol201129Suppl Abstract 5005
   Google Scholar
• MillerDSBlessingJAKrasnerCNPhase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupJ Clin Oncol200927162686269119332726
   PubMed Web of Science ®Google Scholar
• VergoteICalvertHKaniaMKaiserCZimmermannAHSehouliJA randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancerEur J Cancer2009451415142319168349
   PubMed Web of Science ®Google Scholar
• NaumannRWColemanRLBurgerRAPRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancerJ Clin Oncol2013In press
   Web of Science ®Google Scholar
• MabuchiSTeraiYMorishigeKMaintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer modelClin Cancer Res200814237781778919047105
   PubMed Web of Science ®Google Scholar
• HeitzFHarterPBarinoffJBevacizumab in the treatment of ovarian cancerAdv Ther201229972373522941523
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAGynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• SharmaTDhingraRSinghSAflibercept: A novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumorsMini Rev Med Chem201313453054023317499
   PubMed Web of Science ®Google Scholar
• ColemanRLDuskaLRRamirezPTPhase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancerLancet Oncol201112121109111721992853
   PubMed Web of Science ®Google Scholar
• TangPACohenSJKollmannsbergerCPhase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancerClin Cancer Res201218216023603122977191
   PubMed Web of Science ®Google Scholar
• CurtinNJPARP inhibitors for cancer therapyExpert Rev Mol Med20057412015836799
   PubMedGoogle Scholar
• RatnerESSartorelliACLinZPPoly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancerCurr Opin Oncol201224556457122759740
   PubMed Web of Science ®Google Scholar
• LiuXShiYMaagDXIniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorClin Cancer Res201218251052322128301
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• ChenYZhangLHaoQOlaparib: a promising PARP inhibitor in ovarian cancer therapyArch Gynecol Obstet Epub4262013
   Web of Science ®Google Scholar
• AntonyACThe biological chemistry of folate receptorsBlood19927911280728201586732
   PubMed Web of Science ®Google Scholar
• ZhaoRGoldmanIDThe molecular identity and characterization of a Proton-coupled Folate Transporter – PCFT; biological ramifications and impact on the activity of pemetrexedCancer Metastasis Rev200726112913917340171
   PubMed Web of Science ®Google Scholar
• MendelsohnLGShihCChenVJHabeckLLGatesSBShackelfordKAEnzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) in purine biosynthesisSemin Oncol1999262 Suppl 6424710598554
   PubMed Web of Science ®Google Scholar
• MiottiSBagnoliMOttoneFTomassettiAColnaghiMICanevariSSimultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell linesJ Cell Biochem19976544794919178098
   PubMed Web of Science ®Google Scholar
• TomaoFPaniciPBFratiLTomaoSEmerging role of pemetrexed in ovarian cancerExpert Rev Anticancer Ther20099121727173519954283
   PubMed Web of Science ®Google Scholar
• SiuMKKongDSChanHYParadoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcomePloS One2012711e4720123144806
   PubMed Web of Science ®Google Scholar
• NiyikizaCBakerSDSeitzDEHomocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapyMol Cancer Ther20021754555212479273
   PubMed Web of Science ®Google Scholar
• AdjeiAAPemetrexed (ALIMTA), a novel multitargeted neoplastic agentClin Cancer Res20041012 Pt4276s4280s15217974
   PubMed Web of Science ®Google Scholar
• ZhaoRDiop-BoveNVisentinMGoldmanIDMechanisms of membrane transport of folates into cells and across epitheliaAnnu Rev Nutr20113117720121568705
   PubMed Web of Science ®Google Scholar
• KamenBASmithAKFarletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitroCancer Chemother Pharmacol201270111312022644798
   PubMed Web of Science ®Google Scholar
• EbelWRouthierELFoleyBPreclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alphaCancer Immun20077617346028
   PubMedGoogle Scholar
• KonnerJABell-McGuinnKMSabbatiniPFarletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I studyClin Cancer Res20101615288529520855460
   PubMed Web of Science ®Google Scholar
• DosioFMillaPCattelLEC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancersCurr Opin Investig Drugs2010111214241433
   PubMed Web of Science ®Google Scholar
• VlahovIRSanthapuramHKKleindlPJHowardSJStanfordKMLeamonCPDesign and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazideBioorg Med Chem Lett200616195093509616870437
   PubMed Web of Science ®Google Scholar
• VlahovIRLeamonCPEngineering folate-drug conjugates to target cancer: from chemistry to clinicBioconjug Chem20122371357136922667324
   PubMed Web of Science ®Google Scholar
• LeamonCPParkerMAVlahovIRSynthesis and biological evaluation of EC20: a new folate-derived, (99 m)Tc-based radiopharmaceuticalBioconjug Chem20021361200121012440854
   PubMed Web of Science ®Google Scholar
• ReddyJAXuLCParkerNVetzelMLeamonCPPreclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumorsJ Nucl Med200445585786615136637
   PubMed Web of Science ®Google Scholar
• FisherRESiegelBAEdellSLExploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumorsJ Nucl Med200849689990618483093
   PubMed Web of Science ®Google Scholar
• ChenYLChangMCHuangCYSerous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-responseMol Oncol20126336036922265591
   PubMed Web of Science ®Google Scholar
• Herceptin [prescribing information]South San Francisco, CAGenentech, Inc2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdfAccessed April 22, 2013
   Google Scholar
• Zelboraf [prescribing information]South San Francisco, CAGenentech, Inc2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdfAccessed April 22, 2013
   Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• RossJSFletcherJAThe HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapyOncologist19983423725210388110
   PubMedGoogle Scholar
• Safaee ArdekaniGJafarnejadSMTanLSaeediALiGThe prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysisPLoS One2012710e4705423056577
   PubMed Web of Science ®Google Scholar
• GadducciACosioSTanaRGenazanniARSerum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancerCrit Rev Oncol Hematol2009691122718595727
   PubMed Web of Science ®Google Scholar
• VerheijenRHCibulaDZolaPCouncil of the European Society of Gynaecologic OncologyCancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statementInt J Gynecol Cancer201222117017421921803
   PubMed Web of Science ®Google Scholar
• HeflerLAZeillingerRGrimmCPreoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancerGynecol Oncol2006103251251716750560
   PubMed Web of Science ®Google Scholar
• MadsenCVSteffensenKDOlsenDASerial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumabJ Ovarian Res2012512322989094
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicenter, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• EdelmanMJHarbWAPalSEMulticenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lungJ Thorac Oncol20127101618162122982661
   PubMed Web of Science ®Google Scholar
• KuoPNaumannRWSymanowskiJ99 mTc-etarfolatide (EC20) SPECT imaging for the identification of ovarian and non-small cell lung cancer patients who are most likely to benefit from folate-receptor-targeted agent vintafolide (EC145)AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer and Biology TherapyFebruary 27–March 2, 2013San Diego, CA, USA abstract 41
   Google Scholar
• ToffoliGCernigoiCRussoAGalloABagnoliMBoiocchiMOverexpression of folate binding protein in ovarian cancersInt J Cancer19977421931989133455
   PubMed Web of Science ®Google Scholar
• FoxJLFDA moves on breakthrough therapiesNat Biotechnol201331537423657379
   PubMed Web of Science ®Google Scholar
• LeamonCPReddyJAWangYEC0531: A potent folate-targeted tubulysin conjugateProceedings of the 101st Annual Meeting of the American Association for Cancer ResearchApril 17–21, 2010Washington, DC. Philadelphia (PA)AACR
   Google Scholar
  Cancer Res201070Suppl 8 abstract nr 4414
   Google Scholar
• ReddyJABloomfieldADortonRPSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169Proceedings of the 104th Annual Meeting of the American Association for Cancer ResearchApril 6–10, 2013Washington, DC, USA. Philadelphia (PA)AACR2013
   Google Scholar